Regeneus Ltd. (AU:CMB) has released an update.
Cambium Bio Limited has confirmed the significant impact of recent funding information on its stock price and its compliance with all ASX Listing Rules, including rule 3.1 on continuous disclosure. The company became aware of the finalization of the proposed placement on April 5, 2024, and maintains that this information was kept confidential until its official release. Cambium Bio believes that the Cleansing Notice was validly issued, as the final agreement on funding occurred post-merger completion and post-issuance of the notice.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.
